[go: up one dir, main page]

AR011425A1 - Compuestos derivados de sulfamida, su uso, composiciones farmaceuticas que los comprenden y un procedimiento para preparar compuestos derivados de sulfamida - Google Patents

Compuestos derivados de sulfamida, su uso, composiciones farmaceuticas que los comprenden y un procedimiento para preparar compuestos derivados de sulfamida

Info

Publication number
AR011425A1
AR011425A1 ARP980100227A ARP980100227A AR011425A1 AR 011425 A1 AR011425 A1 AR 011425A1 AR P980100227 A ARP980100227 A AR P980100227A AR P980100227 A ARP980100227 A AR P980100227A AR 011425 A1 AR011425 A1 AR 011425A1
Authority
AR
Argentina
Prior art keywords
hydrogen
sulfamide
aralkyl
alkyl
derived compounds
Prior art date
Application number
ARP980100227A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26713422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR011425(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Agouron Pharma filed Critical Hoffmann La Roche
Publication of AR011425A1 publication Critical patent/AR011425A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Detergent Compositions (AREA)

Abstract

Compuestos derivados de sulfamida, que tienen la formula (I) en donde R1 y R2 se eligen independientemente entre hidrogeno, alquilo, alquenilo,haloalquilo, cicloalquilo, cicloalquilalquilo, arilo, aralquilo, heteroarilo, heteroaralquilo,heterocic lo, heterocicloalquilo, heteroalquilo, o-(alquileno)-C(O)-X, o R1 y R2 junto con el átomo de carbono al que están unidos forman un carbociclo o un heterociclo; R3 es hidrogeno, alquilo,alquenilo, haloalquilo, cicloalquilo, arilo,aralquilo, ara lquenilo, heteroarilo, heteroaralquilo, heteroalquenilo, heterocicloalquilo,heteroalquilo, (difenilmetil)-alquilo, o -(alquileno)-C(O)-X; o R3 junto con R1 o R2 y los átomos a los que están unidos forman un grupoheterocicloamino;R10 es -NR11OR12; R20 y R21 se eligen, independientemente, entre hidrogeno, alquilo, heteroalquilo, cicloalquilo, cicloalquilalquilo arilo, aralquilo,aralquenilo, heteroaralquilo, o heteroaralquenilo; o R20 y R21 junto con elátomo de nitrogeno al que están unidos forman un grupo heterocicloamino o unanillo de tetrahidropiridina o hexahidroazepina opcionalmente sustituido; o cualquiera de R20 o R21 junto con R3 forma un grupo alquileno; y sus salesfarmacéuticamenteaceptables, profármacos, isomeros individuales, y mezclas de isomeros, con la condicion de R20 y R21 junto con el átomo de nitrogeno al queestán unidos no formen un anillo morfolino: (i) cuando R1 y R3 son hidrogeno y R2 es aralquilo; o (ii)cuando R1 y R3 junto con los á tomos a los que estánunidos forman un anillo de tetrahidroisoquinolina y R2 es hidrogeno; y compuestos de formula (I) en donde R1, R2 y R3 son como se definieron antes yR10 es -OH; R20 es hidrogeno o alquilo,y R21 es cicloalquilo, arilo, aralquilo, aralquenilo, heteroarilo o heteroaralquenilo; o R20 y R21 junto con
ARP980100227A 1997-01-23 1998-01-20 Compuestos derivados de sulfamida, su uso, composiciones farmaceuticas que los comprenden y un procedimiento para preparar compuestos derivados de sulfamida AR011425A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3671497P 1997-01-23 1997-01-23
US6220997P 1997-10-16 1997-10-16

Publications (1)

Publication Number Publication Date
AR011425A1 true AR011425A1 (es) 2000-08-16

Family

ID=26713422

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100227A AR011425A1 (es) 1997-01-23 1998-01-20 Compuestos derivados de sulfamida, su uso, composiciones farmaceuticas que los comprenden y un procedimiento para preparar compuestos derivados de sulfamida

Country Status (35)

Country Link
EP (1) EP0958287B2 (es)
JP (1) JP3563411B2 (es)
KR (1) KR100377696B1 (es)
CN (1) CN1093125C (es)
AR (1) AR011425A1 (es)
AT (1) ATE223909T1 (es)
AU (1) AU730127B2 (es)
BG (1) BG103586A (es)
BR (1) BR9807508A (es)
CA (1) CA2278694C (es)
DE (2) DE69807845T2 (es)
DK (1) DK0958287T3 (es)
EA (1) EA002810B1 (es)
ES (2) ES2183331T3 (es)
FR (1) FR2758559A1 (es)
GB (1) GB2321641B (es)
HR (1) HRP980036A2 (es)
HU (1) HUP0000941A3 (es)
ID (1) ID22849A (es)
IL (1) IL130802A0 (es)
IS (1) IS5125A (es)
IT (1) IT1298163B1 (es)
MA (1) MA26467A1 (es)
NO (1) NO313635B1 (es)
NZ (1) NZ336625A (es)
OA (1) OA11078A (es)
PA (1) PA8445301A1 (es)
PE (1) PE57399A1 (es)
PL (1) PL334846A1 (es)
PT (1) PT958287E (es)
TN (1) TNSN98012A1 (es)
TR (1) TR199901765T2 (es)
UY (1) UY24854A1 (es)
WO (1) WO1998032748A1 (es)
YU (1) YU34599A (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
HN2000000052A (es) * 1999-05-28 2001-02-02 Pfizer Prod Inc Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos.
ATE356114T1 (de) 1999-06-04 2007-03-15 Astrazeneca Ab Inhibitoren von metalloproteinasen
ATE260251T1 (de) 1999-08-18 2004-03-15 Warner Lambert Co Hydroxamsäurederivate als matrix- metalloproteinase-inhibitoren
DOP2000000107A (es) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas
SK287071B6 (sk) 2000-02-21 2009-11-05 Astrazeneca Ab Deriváty N-hydroxyformamidov substituované piperidínom a piperazínom, farmaceutická kompozícia, ktorá ich obsahuje, spôsob ich prípravy a ich použitie
US20030100548A1 (en) * 2000-02-21 2003-05-29 Barlaam Bernard Christophe Arylpiperazines and their use as metallaproteinase inhibiting agents (mmp)
US6495358B1 (en) * 2000-04-19 2002-12-17 Wichita State University Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes
AU4882101A (en) * 2000-04-28 2001-11-12 Shionogi & Co., Ltd. Mmp-12 inhibitors
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US6492171B2 (en) 2000-05-16 2002-12-10 Isis Pharmaceuticals, Inc. Antisense modulation of TERT expression
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
JP4219810B2 (ja) * 2001-10-26 2009-02-04 塩野義製薬株式会社 Ｍｍｐ阻害作用を有するスルホンアミド誘導体
WO2003082288A1 (en) * 2002-04-03 2003-10-09 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7629341B2 (en) 2002-06-12 2009-12-08 Symphony Evolution, Inc. Human ADAM-10 inhibitors
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
DE10344936A1 (de) * 2003-09-27 2005-04-21 Aventis Pharma Gmbh Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
WO2005110413A2 (en) * 2004-05-19 2005-11-24 Solvay Pharmaceuticals Gmbh Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
CN101084211A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
DE102004060229A1 (de) 2004-12-15 2006-06-29 Sanofi-Aventis Deutschland Gmbh Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen
EP1997804A1 (en) * 2006-03-03 2008-12-03 Shionogi & Co., Ltd. Mmp-13-selective inhibitor
WO2008053913A1 (fr) 2006-11-02 2008-05-08 Shionogi & Co., Ltd. Dérivé de sulfonylurée capable d'inhiber sélectivement mmp-13
WO2008147764A1 (en) * 2007-05-23 2008-12-04 Array Biopharma, Inc. Mmp inhibitors and methods of use thereof
MX2010003148A (es) * 2007-10-12 2010-04-01 Basf Se Procedimiento para la preparacion de diamidas de acido sulfonico.
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
CA2768466C (en) * 2009-07-22 2018-08-14 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
JP6463631B2 (ja) * 2011-06-09 2019-02-06 ライゼン・ファーマシューティカルズ・エスアー Ｇｐｒ−１１９のモジュレータとしての新規化合物
DK3297992T3 (da) 2015-05-22 2020-04-20 Chong Kun Dang Pharmaceutical Corp Heterocykliske alkylderivatforbindelser som selektive histondeacetylase-inhibitorer og farmaceutiske sammensætninger omfattende samme
WO2020070239A1 (en) 2018-10-04 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH617318A5 (en) † 1975-09-30 1980-05-30 Ciba Geigy Ag Microbicidal composition.
US5140009A (en) * 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
US5114937A (en) * 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
IE68045B1 (en) * 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
WO1993006127A1 (en) * 1991-09-17 1993-04-01 Warner-Lambert Company Novel amino acid prodrug renin inhibitors
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
AU683382B2 (en) † 1994-05-04 1997-11-06 Novartis Ag N-sulphonyl and N-sulphinyl amino acid amides as microbiocides
DE19507447A1 (de) † 1995-03-03 1996-09-05 Vitronic Dr Ing Stein Bildvera Verfahren und Schaltung zum Erfassen und Weiterleiten von Videobilddaten in einem PC
CN1131215C (zh) * 1995-11-13 2003-12-17 赫彻斯特股份公司 环和杂环N－取代的α－亚氨基异羟肟酸和羧酸
DK0780386T3 (da) * 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
FR2748026B1 (fr) * 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
WO1998032748A1 (en) 1998-07-30
HUP0000941A2 (hu) 2001-04-28
NO313635B1 (no) 2002-11-04
GB2321641A (en) 1998-08-05
PL334846A1 (en) 2000-03-27
JP2001523222A (ja) 2001-11-20
GB2321641B (en) 2001-04-04
BG103586A (bg) 2000-03-31
DE69807845T2 (de) 2003-06-05
IT1298163B1 (it) 1999-12-20
UY24854A1 (es) 2000-12-29
MA26467A1 (fr) 2004-12-20
CN1250445A (zh) 2000-04-12
AU730127B2 (en) 2001-02-22
PT958287E (pt) 2002-12-31
EA199900643A1 (ru) 2000-04-24
EP0958287B2 (en) 2008-04-09
TR199901765T2 (xx) 1999-10-21
CA2278694C (en) 2006-09-26
ES2136037A1 (es) 1999-11-01
ITMI980091A1 (it) 1999-07-20
EP0958287A1 (en) 1999-11-24
PE57399A1 (es) 1999-06-25
FR2758559A1 (fr) 1998-07-24
NO993587D0 (no) 1999-07-22
KR100377696B1 (ko) 2003-03-29
ES2183331T3 (es) 2003-03-16
DE69807845D1 (de) 2002-10-17
TNSN98012A1 (fr) 2005-03-15
CN1093125C (zh) 2002-10-23
EA002810B1 (ru) 2002-10-31
HRP980036A2 (en) 1998-12-31
BR9807508A (pt) 2000-03-21
PA8445301A1 (es) 2001-07-31
YU34599A (sh) 2002-03-18
ID22849A (id) 1999-12-09
AU6614098A (en) 1998-08-18
EP0958287B1 (en) 2002-09-11
NZ336625A (en) 2001-04-27
DE19802350A1 (de) 1998-07-30
HUP0000941A3 (en) 2002-06-28
CA2278694A1 (en) 1998-07-30
NO993587L (no) 1999-09-22
OA11078A (en) 2003-03-17
IS5125A (is) 1999-07-22
IL130802A0 (en) 2001-01-28
KR20000070398A (ko) 2000-11-25
ES2136037B1 (es) 2000-11-16
GB9801393D0 (en) 1998-03-18
DK0958287T3 (da) 2003-01-20
JP3563411B2 (ja) 2004-09-08
ATE223909T1 (de) 2002-09-15

Similar Documents

Publication Publication Date Title
AR011425A1 (es) Compuestos derivados de sulfamida, su uso, composiciones farmaceuticas que los comprenden y un procedimiento para preparar compuestos derivados de sulfamida
CO4790091A1 (es) Derivados sustituidos de acido 3-sulfonil-propionico
AR012032A1 (es) Compuestos derivados 3'-n-oxido, 3'-n-dimetilamina, 9-oxima eritromicina a y un proceso para su preparacion
ES2221440T3 (es) Derivados de acido aminofenoxiacetico como neuroprotectores.
MY100846A (en) Fungicidal pyridyl imidates
DK554288A (da) Heterocycliske spiro-forbindelser og fremgangsmaade til fremstilling deraf
ES2053508T3 (es) Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos.
ES2062501T3 (es) Aditivos de carbamato para composiciones lubricantes.
ES2059804T3 (es) Procedimiento de preparacion de eteres de oxima de propenona.
AR007969A1 (es) Compuestos derivados de pirroles sustituidos, su utilizacion y composiciones farmaceuticas que contienen tales compuestos
ES8301927A1 (es) Procedimiento de preparacion de acidos azabiciclohexano car-boxilicos y de sus sales
ES2106185T3 (es) 3-carboxiesteroides 17-beta-sustituidos no saturados.
ES2039234T3 (es) Procedimiento para preparar acidos y esteres 1,2,3,4-tetrahidro-6-sustituido-4-aril (o heterociclo)-3-((amino sustituido) carbonil)-2-tioxo (u oxo)-5-pirimidincarboxilicos.
ES8604543A1 (es) Procedimiento para la obtencion de derivados piperazinicos
MX9301045A (es) Procedimiento para preparar antagonistas receptores de fibrinogeno.
CO4910142A1 (es) Compuestos de furano nitrona
ES2062071T3 (es) Procedimiento de preparacion de ((diarilmetoxi) alcoil)-1 pirrolidinas y piperidinas y medicamentos que las contienen.
PE20030611A1 (es) Compuestos basicos lineales que tienen actividad antagonista de nk-2 y sus formulaciones
ES2042030T3 (es) Procedimiento de preparacion de una composicion para inducir y estimular el crecimiento de los cabellos y/o frenar su caida, a base de alquilpoliglicosido y de un derivado de pirimidina.
CO5011085A1 (es) Fosfitos y fosfatos ciclicos derivados de eritromicina
EP0253502A3 (en) Tertiary amine compounds
AR005123A1 (es) Derivados de acidos carboxilicos, procedimiento para su preparracion, composiciones farmaceuticas que los comprenden y empleos de dichos derivados
KR910007939A (ko) 헤테로사이클릭 화합물 및 이의 제조방법
ES2031594T3 (es) Tioeteres aromaticos.
ES454285A1 (es) Procedimiento para preparar derivados de 4-amina trans-deca-hidroquinolina.

Legal Events

Date Code Title Description
FG Grant, registration